The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published on October 12
Trump's drug pricing agreements with major pharma companies signal a fundamental shift in how the U.S. healthcare system operates. Companies that adapt quickly could gain significant competitive advantages.
Firms with strong domestic manufacturing and distribution networks may be better positioned to navigate new pricing pressures whilst maintaining profitability in this evolving landscape.
The move towards most-favoured-nation pricing could create winners and losers across the pharmaceutical sector. Early positioning in adaptive companies could prove rewarding as the industry reshapes itself.
The Trump administration's drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer represent a fundamental shift towards most-favoured-nation pricing. This policy change could reshape industry profitability and create new opportunities for companies that can adapt to the evolving healthcare landscape.
This group focuses on pharmaceutical companies with strong domestic manufacturing capabilities and key players in the healthcare supply chain. These firms may be more resilient to pricing pressures or could benefit from new market dynamics as the industry adapts to government-controlled pricing models.
These stocks were handpicked by professional analysts based on their potential to navigate the new pricing paradigm. The selection includes pharmaceutical producers, distributors, and healthcare service providers positioned to adapt to significant policy changes that may reshape the entire sector.
Market capitalisation breakdown for the basket 'Pharma's New Pricing Paradigm'.
LLY: $788.86B
MRK: $214.78B
CVS: $98.80B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+9
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+11.51%
On average, analysts expect assets in this group to grow 11.51% over the next year.
16 of 19 assets in this group are rated Buy by professional analysts.
